Tags: Genzyme Sanofi Aventis

Sanofi, Genzyme Officials Discuss Terms of Possible Deal

Monday, 10 Jan 2011 12:50 PM

Biotech drugmaker Genzyme Corp. says talks between its financial advisers and those of suitor Sanofi-Aventis have expanded to include representatives of both companies.

The Cambridge, Mass., company says the talks focus on potential terms for a deal and include ways to value right for its experimental multiple sclerosis drug called alemtuzumab.

Genzyme shares rose 2 percent in pre-market trading.

French drugmaker Sanofi-Aventis has been pursuing a deal with Genzyme since last summer. Genzyme has rejected Sanofi's takeover bid of $18.5 billion.

Genzyme stumbled last year after regulators uncovered plant manufacturing problems, but the company says Sanofi's offer fails to account for its recovery and pipeline of developing drugs like alemtuzumab.

© Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Companies
Biotech drugmaker Genzyme Corp. says talks between its financial advisers and those of suitor Sanofi-Aventis have expanded to include representatives of both companies.The Cambridge, Mass., company says the talks focus on potential terms for a deal and include ways to value...
Genzyme Sanofi Aventis
110
2011-50-10
Monday, 10 Jan 2011 12:50 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved